TY - JOUR T1 - A genetic and transcriptomic assessment of the <em>KTN1</em> gene in Parkinson’s disease risk JF - medRxiv DO - 10.1101/2021.03.08.21252688 SP - 2021.03.08.21252688 AU - Anni Moore AU - Sara Bandres-Ciga AU - Cornelis Blauwendraat AU - Monica Diez-Fairen AU - on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC) Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.08.21252688.abstract N2 - Parkinson’s disease (PD) is a progressive neurological disorder caused by both genetic and environmental factors. A recent finding has suggested an association between KTN1 genetic variants and changes in its expression in the putamen and substantia nigra brain regions and an increased risk for PD. Here, we examine the link between PD susceptibility and KTN1 using individual-level genotyping data and summary statistics from the most recent genome-wide association studies (GWAS) for PD risk and age at onset from the International Parkinson’s Disease Genomics Consortium (IPDGC), as well as whole-genome sequencing data from the Accelerating Medicines Partnership Parkinson’s disease (AMP-PD) initiative. To investigate the potential effect of changes in KTN1 expression on PD compared to healthy individuals, we further assess publicly available expression quantitative trait loci (eQTL) results from GTEx v8 and BRAINEAC and transcriptomics data from AMP-PD. Overall, we found no genetic associations between KTN1 and PD in our cohorts but found potential evidence of differences in mRNA expression, which needs to be further explored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging (NIA), and the National Institute of Environmental Health Sciences both part of the National Institutes of Health, Department of Health and Human Services; project numbers 1ZIA-NS003154, Z01- AG000949-02 and Z01-ES101986. In addition, this work was supported by the Department of Defense (award W81XWH-09-2-0128), and The Michael J Fox Foundation for Parkinson's Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants clinical information and genetic samples were obtained with appropriate written consent and local institutional and ethical approval. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Additionally, our project is covered by all relevant, local IRBs from which the data were derived. All data were de-identified prior to sharing with researchers, and therefore, researchers did not have access to any information on the included subjects. As a result, our study design was reviewed by the NIH Office of IRB Operations, and the reviewing body determined that the research activities did not require IRB approval or review. UK Biobank data were obtained under the application number 33601.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe summary statistics from PD meta-analyses that support the findings of this study are available from IPDGC consortium website, https://pdgenetics.org/resources. The whole genome sequencing and transcriptomics data that support the findings of this study are available from AMP-PD website, https://amp-pd.org/. Individual-level genotyping data that support the findings of this study are available from the corresponding author upon reasonable request. All code used in this study is publicly available at https://github.com/ipdgc/IPDGC-Trainees/blob/master/KTN1.md. https://pdgenetics.org/resources https://amp-pd.org/ https://github.com/ipdgc/IPDGC-Trainees/blob/master/KTN1.md ER -